<DOC>
	<DOCNO>NCT00835471</DOCNO>
	<brief_summary>The purpose study assess combination erlotinib chemotherapy ( docetaxel case squamous cell NSCLC pemetrexed case histological type ) superior erlotinib alone acceptable tolerability safety 2nd line treatment patient advanced/metastatic non-small cell lung cancer ( NSCLC ) .</brief_summary>
	<brief_title>2nd Line Erlotinib Treatment With ( Out ) Chemotherapy Advanced Non Small Cell Lung Cancer ( NSCLC )</brief_title>
	<detailed_description>Open randomize multicenter phase II study patiÃ«nts need 2nd line treatment advanced/metastatic NSCLC . Efficacy safety monotherapy erlotinib compare combination therapy erlotinib chemotherapy . In recent study establish pemetrexed activity pronounce non-squamous NSCLC comparison squamous cell carcinoma . Therefore patient non-squamous carcinoma pemetrexed use . As second line treatment NSCLC docetaxel register also usage patient squamous cell carcinoma , docetaxel use patient squamous histology . Chemotherapy limit 4 course . Erlotinib continue disease progression unacceptable toxicity . Erlotinib monotherapy administer continuously . In combination chemotherapy , erlotinib give day 2-16 every course 3 week .</detailed_description>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Erlotinib Hydrochloride</mesh_term>
	<mesh_term>Pemetrexed</mesh_term>
	<criteria>1 . Histologically cytologically confirm NSCLC , locally advanced metastatic disease stage IIIB IV . Evidence disease progression one two cytotoxic treatment regimen include platinum agent . 2 . Complete recovery prior chemotherapy side effect &lt; Grade 2 . 3 . At least one unidimensional measurable lesion meeting RECIST criterion . 4 . ECOG PS 02 . 5 . Age &gt; 18 year . 6 . Adequate organ function , include : Adequate bone marrow reserve : ANC &gt; 1.5 x 109/L , platelet &gt; 100 x 109/L . Hepatic : bilirubin &lt; 1.5 x ULN , AP , ALT , AST &lt; 1.5 x ULN AP , ALT , AST &lt; 5 x ULN acceptable liver tumor involvement Renal : calculate creatinin clearance &gt; 40 ml/min base CockcroftGault formula . 7 . Estimated life expectancy &gt; 12 week . 8 . Male female patient reproductive potential must use approved contraceptive method , appropriate . Female patient childbearing potential must negative serum pregnancy test within 7 day prior study enrollment . 9 . Signed informed consent . 10 . Patient compliance geographical proximity allow adequate follow . 1 . Pregnant lactating woman . 2 . Patients medical risk nonmalignant disease well active uncontrolled infection . 3 . Documented brain metastasis unless patient complete local therapy central nervous system metastases corticosteroid least two week enrollment . 4 . Previous treatment EGFRTKI , nonsquamous histology earlier treatment pemetrexed squamous earlier treatment docetaxel . 5 . Inability interrupt aspirin nonsteroidal antiinflammatory agent 5day period ( 5 day period longacting agent piroxicam ) . 6 . Inability unwillingness take folic acid , vitamin B12 supplementation dexamethasone . 7 . Concomitant treatment experimental drug investigation .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2010</verification_date>
	<keyword>Lung cancer</keyword>
	<keyword>non-small-cell</keyword>
	<keyword>erlotinib</keyword>
	<keyword>chemotherapy</keyword>
</DOC>